← All trials
NCT00616161
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2006
- Primary completion
- Jul 1, 2007
- Completion date
- Aug 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Leadiant Biosciences, Inc.Lead sponsor
- MDS PharmaCollaborator
- Institute of Cardiology, Warsaw, PolandOverall official - principal investigator
- Insitutul de Boli Cardiovasculare C.C. Iliescu Bucuresti, Bucharest - ROMANIAOverall official - principal investigator
- Medical University of WarsawOverall official - principal investigator
- Emergency Hospital Loreasca, BucharestOverall official - principal investigator
- Hospital bieganskieko, LodzOverall official - principal investigator
- Iv Military Hospital, WroclawOverall official - principal investigator
- Alexandria UniversityOverall official - principal investigator
- CC Iliescu Heart Disease Institute, BucharestOverall official - principal investigator
- Northwestern UniversityStudy chair
- University of AthensOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.